In addition to functioning as the therapeutic target of haematological malignancies [11,12], Syk can function as either a tumour suppressor in breast, colorectal, and gastric cancers or a tumour enhancer in lung, pancreatic, ovarian, and squamous cell carcinoma (SCC) of the head and neck [13]. The gene discussed is SYK; the disease is squamous cell carcinoma.